Reliance Strategic Business Ventures, a wholly-owned subsidiary of Reliance Industries (RIL), announced the acquisition of 22.8 million equity shares of Rs 10 each of Strand Life Sciences for a consideration of Rs 393 crore.
A further investment of up to Rs 160 crore is expected to be completed by March 2023. The total investment will translate into about 80.3% of equity share capital in Strand on a fully diluted basis.Incorporated in India on October 6, 2000, Strand is a pioneer of genomic testing in India with bioinformatics software and clinical research solutions to healthcare providers including clinicians, hospitals, medical devices manufacturers and pharmaceutical companies.
Strand's turnover was Rs 88.70 crore, Rs 109.84 crore and Rs 96.60 crore, and net profit (loss) of Rs 8.48 crore, Rs (25.04) crore and Rs (21.66) crore in FY 2021, FY 2020 and FY 2019 respectively.
"The aforesaid investment is part of group's digital health initiatives, to foster affordable access to world class technology and innovation led healthcare ecosystem in India," RIL said in a statement on Friday.
RIL is the largest private sector corporation in India. Its activities span hydrocarbon exploration and production, petroleum refining and marketing, petrochemicals, retail and digital services. The company reported a 7.3% fall in consolidated net profit to Rs 12,273 crore on a 58.6% rise in net sales to Rs 1,39,949 crore in Q1 FY22 over Q1 FY21.
On Friday, shares of RIL jumped 4.12% to close at Rs 2,388.25 on the BSE. The stock hit a record high of Rs 2394.30 in late trade today.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RIL acquires 22.8 mn shares of Strand Life Sciences for Rs 393 crs - Business Standard
Read More
No comments:
Post a Comment